SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 28.01 |
Enterprise Value ($M) | 23.24 |
Book Value ($M) | 20.37 |
Book Value / Share | 3.83 |
Price / Book | 1.38 |
NCAV ($M) | 20.23 |
NCAV / Share | 3.81 |
Price / NCAV | 1.38 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.79 |
Return on Assets (ROA) | -0.48 |
Return on Equity (ROE) | -0.51 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 8.69 |
Current Ratio | 8.69 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 22.86 |
Assets | 23.00 |
Liabilities | 2.63 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | -2.85 |
Operating Income | -17.93 |
Net Income | -16.35 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -11.87 |
Cash from Investing | 13.08 |
Cash from Financing | 0.40 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
3,737 | 20,801 | 17.97 | |
1,721 | 2,882 | 59.72 | |
2,547 | 8,332 | 30.57 | |
3,305 | 34,899 | 9.47 | |
(click for more detail) |
Similar Companies | |
---|---|
LIFE – aTyr Pharma, Inc. | LIPO – Lipella Pharmaceuticals Inc. |
LIXT – Lixte Biotechnology Holdings, Inc. | LPTX – Leap Therapeutics, Inc. |
LQDA – Liquidia Corporation |